Mirikizumab for kids with ulcerative colitis or Crohn’s
Treatments studied
Part of Digestive system clinical trials.
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a child who previously joined one of the listed mirikizumab studies and may benefit from more treatment
- You must have finished the prior study’s last visit and still be staying on mirikizumab
- If you are able to become pregnant, you must agree to pregnancy prevention (contraception) rules
- You must not have had serious safety problems or new issues that make restarting mirikizumab unsafe
- You must not have stopped the study medicine in the prior study in a way that would make restarting unsafe
- You cannot be pregnant or breastfeeding, and you must not have unreoved pre-cancer (adenomatous) colon polyps
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests mirikizumab to reduce inflammation and symptoms in children with Crohn’s disease that is currently active. It may help if your Crohn’s has not improved enough (or stopped working) with at least one other Crohn’s medicine.
This study tests a medication called mirikizumab (an injection) in people over 60 with moderate to severe Crohn's disease or ulcerative colitis. The goal is to see if it effectively reduces inflammation and helps symptoms, while also checking how safe it is for older adults.
This study tests two drugs together (LY4268989 and mirikizumab) in people with moderate to severe ulcerative colitis. It's for those whose current treatments didn't work well enough.
This trial is testing whether a drug called mirikizumab, given alongside surgery to repair anal fistulas, can help heal them better in people with Crohn's disease. It aims to provide a new treatment option that may improve healing and quality of life.
This study tests whether adding mirikizumab to the weight-loss drug tirzepatide helps people with moderate-to-severe ulcerative colitis who also have obesity or overweight. It aims to see if the combination reduces bowel inflammation and helps with weight management.
This study tests risankizumab (a medication that targets inflammation) in young people with ulcerative colitis who haven't improved enough on other treatments. It aims to see if risankizumab can help control symptoms and reduce bowel inflammation.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.